Automated Liquid Handling Systems Market -Size, Share, Outlook Automated Liquid Handling Systems Market PDF Forma

Automated Liquid Handling Systems Market -Size, Share,
Outlook, and Opportunity Analysis, 2018–2026
Automated Liquid Handling Systems Market, by Product Type
(Automated Liquid Handling Workstation, Pipettes & Consumables,
Microplate Reagent Dispensers, and Others), by End User (Hospitals &
Diagnostic Centers, Biotechnological & Pharmaceuticals Companies,
Research and Academic Institutes, and Others), and by Geography
(North America, Latin America, Europe, Asia Pacifc, Middle East, and
Africa)
Automated liquid handling systems are multipurpose tools designed to perform multiple tasks in
laboratories that include sampling, mixing, and combining of liquid samples automatically. The
automated liquid handling system facilitates elimination of sample contamination and reduces
manual work of lab personnel by performing several laboratory tasks. These workstations are
able to measure samples, add reagents, and ensure addition of liquids to bioassays in uniform
pattern. The liquid handling workstations difer in volume of samples that can be handled and
are available with variety of integrated software to maintain the footprint of the tasks carried out
by these instruments.
Download PDF Brochure of Market Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/2021
Automated Liquid Handling Systems Market Dynamics
Pharmaceutical companies are increasingly focusing on conducting number of research and
development activities as well as outsourcing such activities to academic and private research
institutes, which is increasing the number of new laboratory set-ups. This in turn increases
demand for liquid handling systems, thereby fostering the market growth. Moreover,
pharmaceutical companies are increasingly outsourcing their research to privately-based
contract research organizations (CRO) to stay competitive in the exponentially growing
pharmaceutical and biotechnology medicines sector. For instance, in May 2018, Ritter
Pharmaceuticals, Inc.—a developer of novel therapeutic products entered into an agreement with
Medpace—a clinical research organization (CRO)—to conduct the frst of two pivotal Phase 3
clinical trials for RP-G28 among patients with lactose intolerance (LI). In October 2016, Sun
Pharma—an India-based pharmaceutical company—announced plans to increase its research
and development activities by investing in a new R&D unit at Madhya Pradesh, India.